Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Æó¼â¼º Ȳ´Þ¿¡¼­ ´ãµµ ¹è¾× ÀüÈÄÀÇ Cytokine°ú Endotoxin¿¡ ´ëÇÑ ¿¬±¸ Cytokine and Endotoxin before and after External or Internal Biliary Drainage in Malignant Bile Duct Obstruction

´ëÇѼÒÈ­±âÇÐȸÁö 2003³â 41±Ç 6È£ p.493 ~ 498
¼Ò¼Ó »ó¼¼Á¤º¸
°­´ëȯ/Kang DH ÇãÁ¤/±è±¤ÇÏ/¹®ÀçÇö/±Ç´ë½Ä/±èº¸¼®/¾ÈÁø±¤/¼Û±Ù¾Ï/Á¶¸ù/¾ç¿õ¼®/Heo J/Kim GH/Moon JH/Kwon DS/Kim BS/An JK/Song GA/Cho M/Yang US

Abstract

Background/Aims: Malignant biliary obstruction are associated with high postoperative morbidity and mortality. This study was performed to determine the effect of external and internal biliary drainage on plasma concentrations of cytokines and endotoxin. Methods: Twenly-one patients with malignant biliary obstruction were enrolled in this study. They were devided into two groups, PTBD (percutaneous transhepatic biliary drainage) and ERBD (endoscopic retrograde biliary drainage) groups. Then, plasma concentrations of TNF-¥á, sTNFr, interleukin 1¥á (IL-1¥á), interleukin 6 (IL-6), and endotoxin were measured before and after 1 week in PTBD and ERBD groups. Results: Total bilirubin decreased significantly from 13.3¡¾8.2 to 6.2¡¾4.4 mg/dL after PTBD and 7.0¡¾11.2 to 5.3¡¾4.0 mg/dL after ERBD (p=0.005, 0.007, respectively). Plasma sTNFr in PTBD group was 5.1¡¾1.4 before drainage and remained unchanged 5.5¡¾1.5 ng/mL at one week after drainage (p=0.155). Plasma sTNFr in the ERBD group was 5.9¡¾1.5 and 5.6¡¾1.0 ng/mL before and after biliary drainage, respectivedly (p=0.333). There was no significant difference of sTNFr changes between the PTBD and ERBD groups (p=0.113). Moreover, there was no significant difference in endotoxin changes between the PTBD and ERBD groups (p=0.477). Other cytokines changed insignificantly. Conclusions: Both PTBD and ERBD did not affect significantly plasma concentrations of sTNFr and endotoxin. Although ERBD provides a better quality of life and physiologic benefit, it dose not decrease cytokines and endotoxin associated with high morbidity and mortality in patients with malignant biliary obstruction.


¸ñÀû: ¾Ç¼º ´ãµµÆó»öÀº ½Ã¼ú ¹× ¼ö¼ú ÈÄ ½ÅºÎÀü, ÆÐÇ÷Áõ µî°ú °°Àº ³ôÀº ÀÌȯÀ² ¹× »ç¸Á·ü°ú ¿¬°üÀÌ ÀÖ´Ù. ÀÌ·¸³ª ÇÕº´ÁõÀº ´ãµµ ¹è¾×, ƯÈ÷ Á¤»óÀûÀÎ »ý¸®»óÅÂ¿Í À¯»çÇÑ ³»ºÎ ´ãµµ ¹è¾×À» ½Ç½ÃÇÔÀ¸·Î½á ¿¹¹æµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î¿©°ÜÁö°í ÀÖ´Ù. º» ¿¬±¸´Â ¾Ç¼º ´ãµµÇùÂø¿¡¼­ ³»ºÎ ±×¸®°í ¿ÜºÎ ´ãµµ¹è¾× ÀüÈÄ ÇÕº´Áõ°ú °ü·ÃµÈ TNF-¥á, sTNFr, interleukin 1¥á, interleukin 6¿Í °°Àº »çÀÌÅäÄ«Àΰú ³»µ¶¼Ò¿¡ ´ëÇÑ º¯È­¸¦ Æò°¡Çϱâ À§ÇÏ¿© ½ÃÇàÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý: 2001³â 1¿ùºÎÅÍ 2002³â 4¿ù±îÁö ¾Ç¼º ´ãµµÇùÂøÀ¸·Î ´ãµµ¹è¾×¼úÀ» ½ÃÇà¹ÞÀº 21¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. PTBD¸¦ ½ÃÇàÇÑ ±ºÀº 11¸í(³²/¿©: 3/8), Æò±Õ ¿¬·É¡¾Ç¥ÁØÆíÂ÷´Â 61¡¾14¼¼, ´ãµµ¾ÏÀÌ 9¸í, ÃéÀå¾ÏÀÌ 2¸íÀ̾úÀ¸¸ç, ERBD¸¦ ½ÃÇàÇÑ ±ºÀº 10¸í(³²/¿©: 7/3), Æò±Õ ¿¬·É¡¾Ç¥ÁØÆíÂ÷ 65¡¾10¼¼, ´ãµµ¾ÏÀÌ 7¸í, ÃéÀå¾ÏÀÌ 3¸íÀ̾ú´Ù. ´ë»ó±ºÀº ´ã°ü¿°ÀÇ ÀÓ»óÀûÀΠƯ¡Àº ¾ø¾ú´Ù. ÀÏ¹Ý °Ë»ç½Ç °Ë»ç(Ç÷¾× °Ë»ç, °£±â´É °Ë»ç, ½Å±â´É °Ë»ç)¿Í TNF-¥á, interleukin 1¥á, interleukin 6, ³»µ¶¼Ò¸¦ ´ãµµ ¹è¾× Àü ¹× ¹è¾× ÈÄ 7ÀÏ°¿¡ ÃøÁ¤ÇÏ¿´´Ù. °á°ú: ÃÑ ºô¸®·çºóÀº ½Ã¼ú ÀüÈÄ PTBD±º°ú ERBD±º¿¡¼­ °¢°¢ 13.3¡¾8.2¿¡¼­ 6.2¡¾4.4§·/dL, 7.0¡¾11.2¿¡¼­ 5.3¡¾4.0§·/dL·Î ÀǹÌÀÖ°Ô °¨¼ÒÇÏ¿´À¸³ª, ´Ù¸¥ °Ë»çÄ¡ ¼Ò°ßÀº ÀÇ¹Ì ÀÖ´Â º¯È­°¡ ¾ø¾ú´Ù. sTNFr´Â PTBD±º¿¡¼­ ½Ã¼ú ÀüÈÄ °¢°¢ 5.1¡¾1.4, 5.5¡¾1.5 ng/mL¿´À¸¸ç,ERBD±º¿¡¼­ ½Ã¼ú ÀüÈÄ °¢°¢ 5.9¡¾1.3, 5.6¡¾1.0 ng/mL·Î °üÂûµÇ¾úÀ¸¸ç Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ º¯È­´Â ¾ø¾úÀ¸¸ç, sTNFrÀÇ º¯È­´Â PTBD±º°ú ERBD±º¿¡¼­ ½Ã¼ú Àü ÈÄ °¢°¢ 3¸í°ú 1¸í¿¡¼­ °ËÃâµÇ¾ú´Ù. ³»µ¶¼Ò´Â PTBD±º¿¡¼­ ½Ã¼ú ÀüÈÄ °¢°¢ 6.8¡¾1.5, 6.3¡¾1.4 ng/mL¿´À¸¸ç, ERBD±º¿¡¼­ ½Ã¼ú ÀüÈÄ °¢°¢ 6.4¡¾1.1, 6.1¡¾1.3 GMU/mL·Î °üÂûµÇ¾úÀ¸¸ç Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ º¯È­´Â ¾ø¾úÀ¸¸ç, PTBD±º°ú ERBD±ºÀǵΠ±º¿¡¼­ Â÷ÀÌ°¡ ¾ø¾ú´Ù. °á·Ð: sTNFr¿Í ³»µ¶¼Ò´Â ¿ÜºÎ ¹è¾×°ú ºñ±³ÇÏ¿© ³»ºÎ ¹è¾×¿¡¼­ ÀÇ¹Ì ÀÖ´Â º¯È­°¡ °üÂûµÇÁö ¾Ê¾Ò´Ù.

Å°¿öµå

Bile duct obstruction; extrahepatic; Common bile duct neoplasms; Pancreatic neoplasms; Cytokines; Endotoxin; ¾Ç¼º ´ãµµÆó¼â; »çÀÌÅäÄ«ÀÎ; ³»µ¶¼Ò

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS